A major shift in the 2026 global industry is the record-breaking success of "Off-the-Shelf" Stem Cell Therapies. This year, to cater to the need for immediate treatment in acute conditions like GvHD (Graft versus Host Disease), the Cell and Gene Therapy Market has successfully launched several iPSC-derived (induced pluripotent stem cell) products into Phase III trials. This level of "Scalable...
Portuguese 
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek